API | upamostat

upamostat Report issue

Small molecule Experimental

AACT DrugBank MeSH PubChem

Active Ingredient History

NOW

Upamostat is a drug which acts as an inhibitor of the serine protease enzyme urokinase. It is under development as a potential treatment agent for pancreatic cancer, acting to inhibit tumour metastasis. ^Wikipedia

Chemistry

SMILES: CCOC(=O)N1CCN(C(=O)[C@H](Cc2cccc(/C(N)=N\O)c2)NS(=O)(=O)c2c(C(C)C)cc(C(C)C)cc2C(C)C)CC1
InChIKey: HUASEDVYRABWCV-NDEPHWFRSA-N
Mol. Mass: 629.82
ALogP: 4.34 Partition coefficient
ChEMBL Molecule:
upamostat

More Chemistry

Pharmacology

Mechanism of Action:
- Urokinase-type plasminogen activator (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

upamostat | wx-671

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Breast Neoplasms (Phase 2)

COVID-19 (Phase 2/Phase 3)

Pancreatic Neoplasms (Phase 2)

SARS-CoV-2 (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue